Contact FAQ Size: normal large Select Region Europe Product Information Markets About Us Research and Development Investor Relations Employment Previous Next 1 2 3 4 5 Product Search Search by Keyword What's New Press Release 2016/Nov/11 Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH 2016/Nov/02 Initiation of Phase I Clinical Trial for Seasonal Influenza HA Vaccine Sublingual Tablet 2016/Oct/31 Notice Regarding Dividends from Surplus and Revision of Dividend Forecast 2016/Oct/31 Notice Regarding Difference between Consolidated Results Forecast and Actual Results for the Cumulative Second Quarter Ended September 30, 2016 and Revision of Financial Results Forecast for the Fiscal Year 2016 2016/Oct/31 Announcement of Financial Results 2Q, FY2016 MORE RSS Contact / FAQ Contact FAQ Products Product by Industry Product Selector Product by Function Product by Products Group Markets Automotive and Transportation Equipment Housing / Housing Equipment Infrastructure Industries Material Industries Home Appliance and Electrical Industries Displays Electronic Devices Medical Industries Packaging Industries About Us Nitto in Europe Corporate profile Management Concepts Message from the President Sustainability Procurement Access Research & Development R&D strategy and policy Core Technologies Synergy from Technology Combination Development Story Investor Relations Management Policies Financial Data IR Library IR Calendar Stock and Credit Rating Shareholders' Meeting Employment Topics Press Release Contact FAQ Site Map Site Policy Privacy Policy Basic Information Security Policy ©NITTO DENKO CORPORATION. 2013 All rights reserved. Back to Page Top